Stock Analysis
10x Genomics, Inc. Class A Common StockTXG
Sector: Technology · Industry: Laboratory Analytical Instruments
AnalystsHold20 analystsPrice is 67% of the way from the year's low to its high.
Cash covers 701% of debt · Q2 2026.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health75
Risks
- Valuation30
- Profitability0
Weak fundamentals at a demanding price.
Market context
-3.5% today· Z 0.7σ
Bull Case
- ✓Altman Z 25.0 — safe-zone balance sheet
What's happening with TXG
Profile
Strong financial health; profitability, growth, moat, valuation and earnings quality lag behind.
How is each axis scored?
- Valuation30/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (1.3%)5/25
- P/S (14.7x)5/25
- EV/EBIT (n/a)10/25
- Growth12/100 · Weak
- Revenue CAGR (7.0%)12/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-8.6%)0/25
- ROE (-9.1%)0/25
- Net margin (-12.2%)0/25
- Operating margin (-6.2%)0/25
- Financial Health75/100 · Strong
- Altman Z (25.03)25/25
- Current ratio (5.69)25/25
- Interest coverage (-61498.0x)0/25
- Net cash / debt (Net cash)25/25
- Quality35/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (-2.94)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 32.0%)0/25
- Moat25/100 · Weak
- ROIC >12% years (0/7 yrs)0/25
- Median gross margin (75.2%)25/25
- FCF-positive years (1/7 yrs)0/25
- Worst-year net margin (worst -181.6%)0/25
Risk Flags
- ⚠SBC 16.0% of revenue — real dilution cost
- ⚠7 loss-making years in recent history
- ⚠Interest coverage -61498.0× — thin debt cushion
About 10x Genomics, Inc. Class A Common Stock
10x Genomics Inc is a life science technology company based in the United States. Show more
Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Headquarters: PLEASANTON, CA · Employees: 1,178 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
30DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF78.5xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.3%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -5.8%–5.7% · 63rd pct
P/S (TTM)14.67xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 1.4x–43.7x · 87th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales14.6xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio10.96xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-8.6%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-9.1%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-7.3%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-12.2%D
Grade D: LowNet Income / Revenue
Operating Margin-6.2%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin70.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin19.7%A
Grade A: HighFCF / Revenue
True FCF Margin3.7%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
12ERevenue CAGR7.0%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+19.2%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue16.0%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score25.03A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.69xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio5.09xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-61498.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT12.3xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.10xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt7.01xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
35DPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.94A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability32.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.60xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -2800 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -9900 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -9300 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -2000 | |
Saxonov Serge Filed | Saxonov Serge | SellOpen market sale | -1000 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
SULIMAN SHEHNAAZ Filed | SULIMAN SHEHNAAZ | SellOpen market sale | -1222 | |
SULIMAN SHEHNAAZ Filed | SULIMAN SHEHNAAZ | SellOpen market sale | -2270 | |
SULIMAN SHEHNAAZ Filed | SULIMAN SHEHNAAZ | SellOpen market sale | -1325 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years0/7 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)75.2%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years1/7 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-181.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$4.24
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.34
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$78.80M
Total debt obligations (short + long term)
Cash & Equiv.$552.03M
Cash and short-term investments
Net Debt$-473.24MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$825.55M
Shareholders' equity (book value)
Asset / Liability5.04xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$9.05B
Current Market Capitalization
Beta2.00D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: 10x Genomics, Inc. Class A Common Stock (TXG)
TXG is down 3.49% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for 10x Genomics, Inc. Class A Common Stock. Altman Z-Score of 25.03 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.94 suggests a low likelihood of earnings manipulation. 10x Genomics, Inc. Class A Common Stock converts about 20% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- Interest coverage of -61498.0× leaves little room for earnings shocks.
- 10x Genomics, Inc. Class A Common Stock posted a net loss in 7 of 7 available completed fiscal years (2019–2025).
- At a valuation score of 30/100, TXG trades at a premium to its historical multiples.
See how TXG ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TXG moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | Regular | 80.92 | -17.21% | -5.68 |
| Oct 6 | After-hours | 80.58 | -17.56% | -5.79 |
| Sep 24 | Regular | 84.80 | +12.14% | 3.08 |
| Sep 24 | After-hours | 84.92 | +12.30% | 3.12 |
| Sep 23 | Regular | 75.58 | -6.34% | -2.58 |
Frequently Asked Questions about TXG
What is the current 10x Genomics, Inc. Class A Common Stock (TXG) stock price?
TXG is trading at $69.86 at the last market close, down 3.49% on the session. PreMarketPrice tracks TXG pre-market, intraday and after-hours prices.
Is TXG stock a buy right now?
PreMarketPrice's quantitative model rates 10x Genomics, Inc. Class A Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TXG stock overvalued?
10x Genomics, Inc. Class A Common Stock trades at a trailing P/E of n/a and our valuation score rates it 30/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does 10x Genomics, Inc. Class A Common Stock report earnings?
No confirmed earnings date is currently scheduled for TXG. The Earnings section lists recent reports and updates as dates are announced.
What sector does 10x Genomics, Inc. Class A Common Stock operate in?
10x Genomics, Inc. Class A Common Stock operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does 10x Genomics, Inc. Class A Common Stock do?
10x Genomics Inc is a life science technology company based in the United States.
About 10x Genomics, Inc. Class A Common Stock (TXG) Stock
10x Genomics, Inc. Class A Common Stock (TXG) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. As of the latest update, 10x Genomics, Inc. Class A Common Stock is trading at $69.86, down 3.49% on the day with a market capitalization of $9.1 billion. The financial health score for TXG is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TXG stock.
TXG Stock Analysis & Key Metrics
On PreMarketPrice, you can track 10x Genomics, Inc. Class A Common Stock (TXG) across multiple dimensions:
- Pre-market price & movement: Real-time TXG stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TXG with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for 10x Genomics, Inc. Class A Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TXG.
- Sector peers: Compare TXG against 6 other technology stocks on key financial metrics.
Is TXG a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate 10x Genomics, Inc. Class A Common Stock (TXG) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.10x Genomics, Inc. Class A Common Stock (TXG) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.